Raymond James has resumed coverage of Amgen Inc (NASDAQ:AMGN), highlighting its diversified portfolio across various therapeutic areas, which is expected to drive long-term growth. Recent deals, like the Horizon deal, and successful product launches have strengthened its position, particularly in rare diseases. However, concerns about the durability of flagship products and market challenges persist. The company's innovative pipeline in oncology, rare diseases, and obesity shows promise despite uncertainties. The FDA's review of Lumakras and the requirement for an additional study by 2028 are noted. Despite challenges, Amgen's confidence in sustaining margins remains, with the stock's risk-reward balance appearing stable.